Orforglipron vs Setmelanotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo — the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Key Comparison Insights
- Both Orforglipron and Setmelanotide are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to Orforglipron (Human Trials).
Detailed Comparison
| Attribute | Orforglipron | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide. | Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling. |
| Common Dosing | Limited community data available See research protocols | 2-3 mg daily Once daily |
| Administration | Oral tablet daily | Subcutaneous injection daily |
| Typical Duration | Long-term use expected | Long-term / chronic use |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program — the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management. | Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach. In March 2026, FDA approved an expanded indication for acquired hypothalamic obesity in adults and pediatric patients aged 4+. The Phase 3 TRANSCEND trial showed -18.4% placebo-adjusted BMI reduction. |
Frequently Asked Questions: Orforglipron vs Setmelanotide
What is the difference between Orforglipron and Setmelanotide?
Orforglipron is a weight loss peptide that an oral non-peptide glp-1 receptor agonist. fda approved april 1, 2026 under the brand name foundayo — the first daily oral glp-1 pill for weight loss. distribution began april 6, 2026. fda subsequently requested additional post-approval safety data. Setmelanotide is a weight loss peptide that an mc4r agonist for rare genetic obesity disorders. fda approved for specific gene mutations causing obesity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orforglipron or Setmelanotide?
Neither is universally "better" - the choice depends on your specific goals. Orforglipron is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orforglipron and Setmelanotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orforglipron and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.